Adam Frederik Cohen

[vc_row][vc_column width=”1/4″]

[/vc_column][vc_column width=”3/4″]

Professor Adam Frederik Cohen, The Netherlands

H-index 42

Adam Cohen in Professor of Clinical Pharmacology and was until 2018 CEO of the Foundation Centre for Human Drug Research (www.chdr.nl),  a foundation practicing a globally unique mix of a scientific institute that provides services to the pharmaceutical industry and scientific community e.g. the university and the Leiden Medical University Center.

He has supervised more than 30 PhD theses in clinical pharmacology at CHDR and co-authored more than 320 publications in the last 3 decades. Publications in high impact journals that emphasize his leading role in the field of Clinical Pharmacology & Therapeutics and one of the leading figure founder of modern clinical pharmacology in the Dutch medical landscape.

He has developed an online teaching repository: the Teaching Resource System, a curriculum-wide E-learning program about pharmacological mechanisms of action, see https://chdr.nlleducation/trc. This tool is currently used by more than 200.000 users in more than 100 countries.  He is also the founding father of the PaulJanssen Futurelab, a Dutch initiative offering a professional post-graduate curriculum for life science entrepreneurs.

As a clinician, Cohen always remained actively involved in individual patient care as a physician at the department of Nephrology of LUMC.
As clinical pharmacologist, he was involved in the assessment of the incidents that occurred in the TGNL4L2 and BIA tO-2474 trial. His critical reflections led to the implementation of structured risk analysis in protocols, the EMA First-in-Human guideline and to practical tools such as the lnvestigator’s Brochure Derisk Analyzer tool (https://www.ib-derisk.orelloein/), reflecting both his strategic vision and practical, hands-on mentality. His diligent view on drug development also led to the concept of rational drug development, considering drugs as prototypes instead of routine programs in a sequential “phase system”. This approach was defined as “question-based drug development” (QbD) and has led to international awareness and the successful conduct of more than 300 clinical trials at CHDR only in the last decade.

Dr Cohen edited the Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde)  and is Editor-in-Chief of the British Journal of Clinical Pharmacology (BJCP). Between 1999 and 2011 he was vice-chairman of the Netherlands Competent Authority for Human Research (CCMO) and as such responsible for the formation of the regulatory policy for research in humans. He is a member of the supervisory Board of the Rotterdam Eye hospital and a member of the Scientific Advisory Council of the German Institute for Aerospace Research and active in several international committees for scientific advice. He is the current recipient of the Lilly Prize of the British Pharmacological Society.

Dr Cohen has performed several extracurricular activities in volunteer organisations. During a period of several weeks, he volunteered as a relief physician for refugees on the Greek island of Lesbos during the peak of the crisis in January 2016. He is an active clarinet and bass clarinet player and is an experienced yacht skipper on the North Sea.

[/vc_column][/vc_row]

[vc_row][vc_column]
[wm_tabs active=”1″ ]

[wm_item title=”Nomination Letter”]

Letter of nomination

With this letter the Dutch community in Clinical Pharmacology and Therapeutics would like to motivate the nomination of Professor Adam Cohen, MD, PhD, FFPM, FBPhS, FACCP for the EACPT Prize 2019 for Lifetime Achievement in Clinical Pharmacology. Professor Adam Cohen has been selected for his life-long commitment and exceptional achievements in our field.

After successful doctorate degrees in pharmacy (1979) and medicine (1981) from Leiden State University, The Netherlands, dr Cohen joined the department of Clinical Pharmacology of the Wellcome Research Laboratories in Beckenham, UK. Here, he obtained experience in early drug development and was trained in clinical pharmacology under the guidance of among others Nobel Prize laureates professor James Black and professor John Vane. At Wellcome, Cohen’s work led to a PhD thesis about the development of the antihistamine acrivastine and antiepileptic lamotrigine in1986, under supervision of Prof. Dr. Douwe Breimer. His research with lamotrigine was renowned for its large educational and clinical impact. Eventually lamotrigine became the second bestselling drug of GSK. After further training in internal medicine and nephrology at King’s College Hospital in London, he returned to Wellcome Biotech, one of the first biotech companies in the world. There he worked as European Clinical project leader for t-PA which furthered his knowledge and expertise in large scale clinical trials. Already in the early stage of his career, dr Cohen became a member of thesteering committee of the prolific and ground-breaking lnternational Study of lnfarct Survival (lSlS)clinical trials in Oxford. Here, he worked with professor Richard Peto and professor Rory Collins who visionary and lasting changed the landscape of large scale clinical research.

His success made Cohen a renowned researcher in the field of clinical pharmacology. ln 1987, he returned to Leiden, the Netherlands to set up a professional clinical pharmacology institute, the Centre for Human Drug Research (CHDR). CHDR was founded as a foundation practicing a globally unique mix of a scientific institute that provides services to the pharmaceutical industry and scientific community e.g. the university and the Leiden Medical University Center. Dr Cohen became CEO from 1987 to 2O17, and during this period, CHDR grew to its current size (-200 FTEs). He has supervised more than 30 PhD theses in clinical pharmacology at CHDR and co-authored more than 320 publications in the last 3 decades. Publications in high impact journals, such as The Lancet, Annual Revisions of Pharmacology Toxicology and Reviews Nature Drug Discovery, emphasize his leading role in the field of Clinical Pharmacology & Therapeutics. Together with with some Leiden colleagues from the Faculty of BioPharmaceutical sciences (including professor Prof. Dr. Douwe Breimer andProf. Dr. Meindert Danhof), he became the leading figure founder of modern clinical pharmacology in the Dutch medical landscape. During his career he professionalized both research and education in clinical pharmacology without losing touch with the actual experimental work. He always worked (and still works) with undergraduate students and PhD fellows on a daily basis. As a result dr Cohen has been a mentor for many clinical pharmacologists also from outside the Netherlands that were trained at CHDR under his guidance. ln addition, long lasting collaborations with clinical pharmacology departments in the Netherlands and internationally were established. To name just two of these: professor Cohen has established a collaboration with professor Eiji Uchida (president Japanese Society of Clinical Pharmacology) at Showa University, Tokyo, Japan and professor David Webb (President of the British Pharmacological Society and professor of clinical pharmacology) at Edinburgh, Scotland, UK.

Also, together with his colleagues at Leiden University Medical Center he has been teaching pharmacology and therapeutics at the Leiden University Medical Centre and developed an online teaching repository: the Teaching Resource System, a curriculum-wide E-learning program about pharmacological mechanisms of action, see https://chdr.nlleducation/trc. This tool is currently used by more than 200.000 users in more than 100 countries including US, Australia, UK, and Germany. The website has more than 3.000.000 reads demonstrating its utility and wide spread acceptance of this unique resource. He is also the founding father of the Paul Janssen Futurelab, a Dutch initiative offering a professional post-graduate curriculum for life science entrepreneurs.

As a clinician, Cohen always remained actively involved in individual patient care at the department of nephrology of the Leiden University Medical Centre where he has an own out-patient clinic. To his opinion, the connection with individual patients is of utmost importance for a clinical pharmacologist. Cohen: “Research, otherwise would make me deal with groups only.” To date, hestill attends weekly renal pathology meetings, joins grand rounds and consults his patients with great enthusiasm.

As policy maker, dr Cohen has been extremely influential both nationally and internationally. He served as vice chairman of the Central Ethics Committee and Competent Authority for Clinical trials in the Netherlands and this work gave him a wide ranging experience in governmental/political affairs. He was chair of the implementation committee for the EU Clinical Trial Directive in the Netherlands. This led to the smooth implementation of the directive in the EU, being widely acknowledged as the Dutch Model with some envy. ln addition, he chaired several committees dealing with irregularities in research, in industry and the Ministry. He was also representing the Netherlands in the EU negotiations on the implementation of the new EU directive in Brussels andLondon, supported by a working party at the Ministry of Health. As clinical pharmacologist, he was involved in the assessment of the incidents that occurred in the TGNL4L2 and BIA tO-2474 trial. His critical reflections led to the implementation of structured risk analysis in protocols, the EMA First-in-Human guideline and to practical tools such as the lnvestigator’s Brochure Derisk Analyzer tool (https://www.ib-derisk.orelloein/), reflecting both his strategic vision and practical, hands-on mentality. His diligent view on drug development also led to the concept of rational drug development, considering drugs as prototypes instead of routine programs in a sequential “phase system”. This approach was defined as “question-based drug development” (QbD) and has led to international awareness and the successful conduct of more than 300 clinical trials at CHDR only in the last decade.

Regarding his publishing activities, dr Cohen has been (and still is) a role model for many students, researchers and clinicians. He edited the Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde) and was involved in the successful repositioning of the Journal and joined the executive editorial board of the British Journal of Clinical Pharmacology (BJCP). Since 2014, he is the editor-in-chief of BJCP, being one of the highest ranked journals in the field.

Dr Cohen has performed several extracurricular activities in volunteer organisations. During a period of several weeks, he volunteered as a relief physician for refugees on the Greek island of Lesbos during the peak of the crisis in January 2016. He is an active clarinet and bass clarinet player and is an experienced yacht skipper on the North Sea.

As of January 2018, Cohen stepped down as CEO to continue as Director lnnovation Services at CHDR. On November 9th 2018, professor Cohen will become an emeritus professor of ClinicalPharmacology at Leiden University after 24 inspiring years with a well-acknowledged legacy. This legacy is indelible, ranging from the inception of a world-leading clinical pharmacology research institute with 200 FTEs to the set-up of a modernized E-learning curriculum about pharmacological mechanisms of action at the Leiden Medical school.

Altogether, we believe that Prof. Dr. Adam Cohen is a broadly trained professional with many faces. From the perspective of a clinician, researcher, entrepreneur and policy advisor, he was able to make a change on the (inter) national playground of clinical pharmacology research and education, patient care, industry and EU legislations. From the perspective of an innovator, he was responsible for the introduction of several commonly used and paradigm shifting tools, such as question-based drug development and rational risk analysis in study protocols. From a human perspective, his innovative and visionary way of thinking has never stopped him from keeping in touch with his patients. We are confident that Cohen’s dedication, drive and enthusiasm will continuously inspire students, fellow researchers and clinicians, at the present time and in the future.

ln conclusion, we wholeheartedly nominate professor dr Adam Cohen to be awarded the EACPTLifetime Achievement in Clinical Pharmacology because of his exceptional track record of achievements in the international development of Clinical Pharmacology and Therapeutics.

The nomination letter was signed by Professor Kees Kramer, MD, PhD

Nijmegen, 30 October 2018

view original nomination letter

 

[/wm_item]

[wm_item title=”Curriculum Vitae”]

Adam Frederik Cohen, MD PhD FFPM FBPhS FACCP

DATE OF BIRTH: 08.11.1952
PLACE OF BIRTH: Haarlem, the Netherlands
NATIONALITY : Dutch
STATUS: married, three children
Registration Physician: 79020485001; pharmacist: 29020485017
QUALIFICATIONS
Doctoral degree in Pharmacy, State University, Leiden, 1978.
Qualification in Pharmacy, State University, Leiden, 1979Doctoral degree in Medicine, State University, Leiden, 1980.
Qualification in Medicine, State University, Leiden, 1981.
ECFMG examination, 1980.
Ph.D., State University, Leiden 1986.
Member of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom (MFPM), 1996.

MEMBERSHIP OF SOCIETIES
British Pharmacological Society
British Association for Psychopharmacology
Dutch Society for Clinical Pharmacology and Biopharmaceutics (full member)
Royal Dutch Pharmaceutical Society
American College of Clinical Pharmacology
American Society for Clinical Pharmacology and Therapeutics (ASCPT).
American Society of Nephrology

HONOURS
Fellowship of the Faculty of Pharmaceutical Medicine of the Royal College of Medicine of the UK (FFPM)
Fellowship of the American College of Clinical Pharmacology (2009) (FCP)
Fellowship of the British Pharmacological Society (FBPharmacolS)

PRESENT EMPLOYMENT
May 1987   CEO, Centre for Human Drug Research, Leiden, the Netherlands.Staff Physician, Hypertension Clinic, Department of Nephrology Leiden University Medical Centre. Leiden, the Netherlands
March 1994   Professor of Clinical Pharmacology, Leiden University
2006-2013  Chief executive of Promasys BV, a company producing data management software for clinical trials.
2014  Non-executive director of Omnicomm a company producing data management software in Fort Lauderdale USA (Nasdaq OMCM)
2014  Member of the non-executive board of the Rotterdam Eye Hospital.Member of the Patient Care Safety committee.
Jan 2018  Research Director Innovation Services, CHDR, Leiden, the Netherlands

OTHER ACTIVITIES

Past
Member of the Steering Committee of the ISIS study group (International Studies of Infarct Survival, Oxford, UK)
Member of the Scientific Advisory Council of the Dutch Thrombosis Foundation.
Member of the editorial board of the British Journal of Clinical Pharmacology.
Member of the National Committee for the coordination of AIDS research in the Netherlands.
Member of the section Medicine of the Health Council of the Netherlands (Independent Advisory Body to the Minister of Health).
Executive editor British Journal of Clinical Pharmacology, until 1-1-2004
Academy of Medical Sciences UK Member of expert forum on early clinical development of drugs
Abstract Committee Dutch Society for Clinical Pharmacology
Chairman, Implementation Working group for the EU Directive on Clinical trials in the Netherlands (Ministry of Health)
Editor Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde)
Vice chairman of the Central Ethics Committee and Competent Trial Authority of the Netherlands (CCMO).
Faculty member and member of the advisory board of the European Course in Pharmaceutical Medicine (University of Basel)
Member of the scientific advisory board of Sanquin (Netherlands Blood Transfusion Service)
Chairman CORR foundation for ophthalmic research in Rotterdam
European editor of the British Journal of Clinical Pharmacology
Member of the Medical Sciences Committee of Science Europe (Representing the European Science funding agencies in the EU)
Chairman of the Alumni Association of Leiden University Medical School
Current
Health Council of the Netherlands (Independent Advisory Body to the Minister of Health)
Member of the Council for Medical Sciences of the Royal Netherlands Academy of Science
Member of the board of the Alumni Association of Leiden University Medical School
Chairman and founder of the LeidenFutureLab a new school for scientific entrepeneurs established by the Ministry of Health of the Netherlands in association with Leiden University
Editor-in-Chief of the British Journal of Clinical Pharmacology
Member of the scientific advisory board of the Netherlands Diabetes Patients Association

DETAILS OF PREVIOUS EMPLOYMENT
1980 – 1981 Pre-Registration clinical training at Leiden University Hospital, St. Elisabeth Hospital, Leiden and Bronovo Hospital, The Hague
1981-1984 Department of Clinical Pharmacology, Wellcome Research Laboratories, Research physician.
1984  Senior house officer, Medicine and Nephrology, Dulwich Hospital, London.
1984 – 1987  Department. Clinical research physician, Wellcome Research Laboratories, Beckenham, Kent and Research Registrar Department of Nephrology Dulwich Hospital ,London, UK.

ADDITIONAL TRAINING
1990  Advanced training in biomedical research management – Harvard Business School and School of public health; Copenhagen, Denmark.
1996  Strategic Research and Development Management – INSEAD, Fontainebleau, France.
2002  Strategic management of services –INSEAD, Fontainebleau, France
2009  ProMaSys version 6 training; in house; ProMaSys BV by Frans Bouwmeester
2014  Immediate Life Support (ILS) /Advanced Life Support (ALS); RAVHM, in house;
2017 Update medical Research Involving Human Subjects Act (WMO) & GCP; Tapas Group; In house;

EDUCATIONAL ACTIVITIES
1990-   Responsible for the teaching program in pharmacology and clinical pharmacology to medical students in Leiden University Medical Centre
2000-   Responsible for the training of clinical pharmacologists in the post graduate training program of the Dutch Association for Clinical Pharmacology.
Lectures (250+) to international and national scientific organisations

CONSULTANCY
10+ consultancy assignments to international major pharmaceutical industries and biotechnology industry regarding strategy for early drug development, regulatory strategy and scientific management.
Certified expert witness in several law courts of the Netherlands
Advisor to investment funds in the health industry

download CV

[/wm_item]

[wm_item title=”Publications”]

Adam Cohen has been an author of more than 300 original papers in the international scientific literature.

1. Aldenkamp AP, Baker G, Pieters MS, Schoemaker HC, Cohen AF, Schwabe S. The Neurotoxicity Scale: the validity of a patient-based scale, assessing neurotoxicity. Epilepsy Res. 1995;20(3):229-39.

2. Alvarez-Jimenez R, Hart EP, Prins S, de Kam M, van Gerven JMA, Cohen AF, et al. Reversal of mecamylamine-induced effects
in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses. Br J Clin Pharmacol. 2018;84(5):888-99.

3. Blauw GJ, Westendorp RG, Srivastava N, Burggraaf K, Frolich M, Simons R, et al. Hypoxia-induced arterial endothelin does not
influence peripheral vascular tone. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S242-3.

4. Boeijinga JK, van Meegen E, van den Ende R, Schook CE, Cohen AF. Lack of interaction between tramadol and coumarins. J
Clin Pharmacol. 1998;38(10):966-70.

5. Boeijinga JK, van Meegen E, van den Ende R, Schook CE, Cohen AF. Is there interaction between tramadol and
phenprocoumon? Lancet. 1997;350(9090):1552-3.

6. Boot JD, de Haas S, Tarasevych S, Roy C, Wang L, Amin D, et al. Effect of an NK1/NK2 receptor antagonist on airway
responses and inflammation to allergen in asthma. Am J Respir Crit Care Med. 2007;175(5):450-7.

7. Boot JD, De Haas SL, Van Gerven JM, De Smet M, Leathem T, Wagner J, et al. MK-0873, a PDE4 inhibitor, does not influence
the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. 2008;21(3):573-7.

8. Boot JD, de Kam ML, Mascelli MA, Miller B, van Wijk RG, de Groot H, et al. Nasal nitric oxide: longitudinal reproducibility
and the effects of a nasal allergen challenge in patients with allergic rhinitis. Allergy. 2007;62(4):378-84.

9. Boot JD, Tarasevych S, Sterk PJ, Schoemaker RC, Wang L, Amin D, et al. Reversal of the late asthmatic response increases
exhaled nitric oxide. Respir Med. 2005;99(12):1591-4.

10. Boots I, Sukhai RN, Klein RH, Holl RA, Wit JM, Cohen AF, et al. Stimulation programs for pediatric drug research–do children
really benefit? Eur J Pediatr. 2007;166(8):849-55.

11. Broeyer FJ, Osanto S, Ritsema van Eck HJ, van Steijn AQ, Ballieux BE, Schoemaker RC, et al. Evaluation of biomarkers for
cardiotoxicity of anthracyclin-based chemotherapy. J Cancer Res Clin Oncol. 2008;134(9):961-8.

12. Broeyer FJ, Osanto S, Suzuki J, de Jongh F, van Slooten H, Tanis BC, et al. Evaluation of lecithinized human recombinant super
oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients. Br J Clin Pharmacol. 2014;78(5):950-60.

13. Broeyer FJ, van Aken BE, Suzuki J, Kemme MJ, Schoemaker HC, Cohen AF, et al. The pharmacokinetics and effects of a long-
acting preparation of superoxide dismutase (PC-SOD) in man. Br J Clin Pharmacol. 2008;65(1):22-9.

14. Buijs MM, Burggraaf J, Langendonk JG, Schoemaker RC, Frolich M, Arndt JW, et al. Hyposomatotropism blunts lipolysis in
abdominally obese women. J Clin Endocrinol Metab. 2002;87(8):3851-8.

15. Buijs MM, Burggraaf J, Wijbrandts C, de Kam ML, Frolich M, Cohen AF, et al. Blunted lipolytic response to fasting in
abdominally obese women: evidence for involvement of hyposomatotropism. Am J Clin Nutr. 2003;77(3):544-50.

16. Buijs MM, Romijn JA, Burggraaf J, De Kam ML, Cohen AF, Frolich M, et al. Growth hormone blunts protein oxidation and
promotes protein turnover to a similar extent in abdominally obese and normal-weight women. J Clin Endocrinol Metab. 2002;87(12):5668-

17. Buijs MM, Romijn JA, Burggraaf J, de Kam ML, Frolich M, Ackermans MT, et al. Glucose homeostasis in abdominal obesity:
hepatic hyperresponsiveness to growth hormone action. Am J Physiol Endocrinol Metab. 2004;287(1):E63-8.

18. Burggraaf J, Kemme MJ, Muller LM, Schoemaker RC, Cohen AF. The influence of the hand circulation on the assessment of
venous distensibility of the human forearm with venous occlusion plethysmography. Br J Clin Pharmacol. 2000;50(6):621-3.

19. Burggraaf J, Lalezari S, Emeis JJ, Vischer UM, de Meyer PH, Pijl H, et al. Endothelial function in patients with hyperthyroidism
before and after treatment with propranolol and thiamazol. Thyroid. 2001;11(2):153-60.

20. Burggraaf J, Schoemaker HC, Cohen AF. Assessment of changes in liver blood flow after food intake–comparison of ICG
clearance and echo-Doppler. Br J Clin Pharmacol. 1996;42(4):499-502.

21. Burggraaf J, Schoemaker HC, Kroon JM, Huisman L, Kluft C, Cohen AF. Influence of 1-desamino-8-D-vasopressin on

endogenous fibrinolysis, haemodynamics and liver blood flow in healthy subjects. Clin Sci (Lond). 1994;86(5):497-503.

22. Burggraaf J, Schoemaker RC, Kroon JM, Cohen AF. The influence of nifedipine and captopril on liver blood flow in healthy
subjects. Br J Clin Pharmacol. 1998;45(5):447-51.

23. Burggraaf J, Schoemaker RC, Lentjes EG, Cohen AF. Sorbitol as a marker for drug-induced decreases of variable duration in
liver blood flow in healthy volunteers. Eur J Pharm Sci. 2000;12(2):133-9.

24. Burggraaf J, Schoemaker RC, Terpstra IJ, Cohen AF. A phase I double-blind, placebo-controlled, single rising dose study to
determine the safety, tolerability, and pharmacokinetics of oral YM934 in healthy male volunteers. J Clin Pharmacol. 1998;38(1):45-53.

25. Burggraaf J, Tulen JH, Lalezari S, Schoemaker RC, De Meyer PH, Meinders AE, et al. Sympathovagal imbalance in
hyperthyroidism. Am J Physiol Endocrinol Metab. 2001;281(1):E190-5.

26. Burggraaf J, van Haarst AD, Fockens P, Schoemaker HC, Krauwinkel WJ, Cohen AF. The gastrointestinal passage and release
of beclomethasone dipropionate from oral delivery systems in ileostomy volunteers. Br J Clin Pharmacol. 1998;46(3):207-14.

27. Burggraaf J, Westendorp RG, in’t Veen JC, Schoemaker RC, Sterk PJ, Cohen AF, et al. Cardiovascular side effects of inhaled
salbutamol in hypoxic asthmatic patients. Thorax. 2001;56(7):567-9.

28. Cath DC, Gijsman HJ, Schoemaker RC, van Griensven JM, Troost N, van Kempen GM, et al. The effect of m-CPP on tics and
obsessive-compulsive phenomena in Gilles de la Tourette syndrome. Psychopharmacology (Berl). 1999;144(2):137-43.

29. Cohen AF. On authorship in the BJCP. Br J Clin Pharmacol. 2017;83(10):2127-30.

30. Cohen AF. [The life cycle of clinical drug research]. Ned Tijdschr Geneeskd. 2017;161:D1576.

31. Cohen AF. Developing drug prototypes: pharmacology replaces safety and tolerability? Nat Rev Drug Discov. 2010;9(11):856

32. Cohen AF. Methods in clinical pharmacology–a tale of two worlds. Br J Clin Pharmacol. 2008;66(5):585-7.

33. Cohen AF. [The pharmaceutical industry in uproar]. Ned Tijdschr Geneeskd. 2005;149(19):1074.

34. Cohen AF. [European guideline for the quality of non-commercial clinical trials: elegant implementation in the Netherlands via
the amended Dutch Medical Research Involving Human Subjects Act]. Ned Tijdschr Geneeskd. 2003;147(31):1493-5.

35. Cohen AF. [Class substitution of medicines–between cost reduction and the position of professionals in health care]. Ned
Tijdschr Geneeskd. 2002;146(12):551-3.

36. Cohen AF. [Medical research and the pharmaceutical industry. Uneasy bedfellows or a prenuptial agreement?]. Ned Tijdschr
Geneeskd. 2001;145(30):1438-42.

37. Cohen AF. [Clinical researchers and the pharmaceutic industry. The research contract is not an addendum]. Ned Tijdschr
Geneeskd. 1999;143(26):1345-9.

38. Cohen AF. [Scratch artifacts on the back; scientific research with reference to an advertisement]. Ned Tijdschr Geneeskd.
1993;137(51):2659.

39. Cohen AF, Ashby L, Crowley D, Land G, Peck AW, Miller AA. Lamotrigine (BW430C), a potential anticonvulsant. Effects on
the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol. 1985;20(6):619-29.

40. Cohen AF, Burggraaf J, van Gerven JM, Moerland M, Groeneveld GJ. The use of biomarkers in human pharmacology (Phase I)
studies. Annu Rev Pharmacol Toxicol. 2015;55:55-74.

41. Cohen AF, Burggraaf K, de Boer A, Kluft C. Clearance of plasminogen activator–a major determinant of plasma concentration:
therapeutic and diagnostic implications. Ann N Y Acad Sci. 1992;667:443-9.

42. Cohen AF, Cohen BL. Tests of the linearity assumption in the dose-effect relationship for radiation-induced cancer. Health Phys.
1980;38(1):53-69.

43. Cohen AF, Dubois EA, van Bronswijk H. [New drugs; omalizumab]. Ned Tijdschr Geneeskd. 2006;150(52):2871-2.

44. Cohen AF, Dubois EA, van Bronswijk H. [New drugs; palifermin]. Ned Tijdschr Geneeskd. 2006;150(50):2753-4.

45. Cohen AF, Dubois EA, van Bronswijk H. [New medications; erlotinib]. Ned Tijdschr Geneeskd. 2006;150(49):2703-4.

46. Cohen AF, Hamilton M, Philipson R, Peck AW. The acute effects of acrivastine (BW825C), a new antihistamine, compared with
triprolidine on measures of central nervous system performance and subjective effects. Clin Pharmacol Ther. 1985;38(4):381-6.

47. Cohen AF, Hamilton MJ, Liao SH, Findlay JW, Peck AW. Pharmacodynamic and pharmacokinetics of BW 825C: a new
antihistamine. Eur J Clin Pharmacol. 1985;28(2):197-204.

48. Cohen AF, Hamilton MJ, Peck AW. The effects of acrivastine (BW825C), diphenhydramine and terfenadine in combination with
alcohol on human CNS performance. Eur J Clin Pharmacol. 1987;32(3):279-88.

49. Cohen AF, Harkin N, Posner J. Cardiovascular effects of a novel enkephalin analogue, 443C81, in humans. J Cardiovasc
Pharmacol. 1990;16(3):455-60.

50. Cohen AF, Kroon R, Schoemaker HC, Breimer DD, Van Vliet-Verbeek A, Brandenburg HC. The bioavailability of digoxin from
three oral formulations measured by a specific h.p.l.c. assay. Br J Clin Pharmacol. 1993;35(2):136-42.

51. Cohen AF, Kroon R, Schoemaker R, Hoogkamer H, van Vliet A. Influence of gastric acidity on the bioavailability of digoxin.
Ann Intern Med. 1991;115(7):540-5.

52. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in
normal humans. Clin Pharmacol Ther. 1987;42(5):535-41.

53. Cohen AF, Loke YK, Ferro A, Lewis LD, Somogy A, Ritter JM. Editors’ report, November 2010. Br J Clin Pharmacol. 2011;71

54. Cohen AF, Mattie H. Salivary electrolytes in the detection of digoxin intoxication. Neth J Med. 1979;22(5):149-52.

55. Cohen AF, Mitsudo S, Ruben RJ. Nasopharyngeal teratoma in the neonate. Int J Pediatr Otorhinolaryngol. 1987;14(2-3):187-95.

56. Cohen AF, Posner J. Effects of two antihistamine drugs on actual driving performance. Br Med J (Clin Res Ed).
1984;288(6421):935.

57. Cohen AF, Posner J, Ashby L, Smith R, Peck AW. A comparison of methods for assessing the sedative effects of
diphenhydramine on skills related to car driving. Eur J Clin Pharmacol. 1984;27(4):477-82.

58. Cohen AF, Ritter JM. Industrialized research in the BJCP: a neo-Luddite view. Br J Clin Pharmacol. 2012;74(6):903-6.

59. Cohen AF, Tiemstra JD. Diagnosis and treatment of rosacea. J Am Board Fam Pract. 2002;15(3):214-7.

60. Cohen AF, van Bronswijk H. [New drugs; ivabradine]. Ned Tijdschr Geneeskd. 2006;150(48):2646-7.

61. Cohen AF, van Bronswijk H. [New drugs; nitisinone]. Ned Tijdschr Geneeskd. 2006;150(46):2541-2.

62. Cohen AF, van Bronswijk H. [New medications; ziconotide]. Ned Tijdschr Geneeskd. 2006;150(44):2427-8.

63. Cohen AF, van Bronswijk H. [New medications; zonisamide]. Ned Tijdschr Geneeskd. 2006;150(42):2313.

64. Cohen AF, van Bronswijk H. [New medications; bevacizumab]. Ned Tijdschr Geneeskd. 2006;150(40):2194-5.

65. Cohen AF, van Hall MA, van Harten J, Schoemaker RC, Johansson P, Breimer DD, et al. The influence of infusion rate on the
hemodynamic effects of felodipine. Clin Pharmacol Ther. 1990;48(3):309-17.

66. Cohen AF, Warman SP. Upper airway obstruction secondary to warfarin-induced sublingual hematoma. Arch Otolaryngol Head
Neck Surg. 1989;115(6):718-20.

67. Cohen J, Burggraaf J, Schoemaker RC, Sterk PJ, Cohen AF, Diamant Z. Relationship between airway responsiveness to
neurokinin A and methacholine in asthma. Pulm Pharmacol Ther. 2005;18(3):171-6.

68. Collins, R Flather, M Parish, S Sleight, P, Cohen AF, et al. ISIS-4 – A randomized factorial trial assessing early oral
captopril, oral mononitrate, and intravenous magnesium-sulfate in 58,050 patients with suspected acute myocardial-infarction. The Lancet.
1995;345 (8951): 669-85.

69. Damiano A, Glickman AB, Rubin JS, Cohen AF. Ectopic thyroid tissue presenting as a midline neck mass. Int J Pediatr
Otorhinolaryngol. 1996;34(1-2):141-8.

70. de Boer A, Cohen AF. Digoxin and mortality: lessons for observational studies. Br J Clin Pharmacol. 2016;81(1):4-5.

71. de Boer A, Danhof M, Cohen AF, Magnani HN, Breimer DD. Interaction study between Org 10172, a low molecular weight
heparinoid, and acetylsalicylic acid in healthy male volunteers. Thromb Haemost. 1991;66(2):202-7.

72. de Boer A, Kluft C, Dooijewaard G, Kasper FJ, Kroon JM, Breimer DD, et al. Influence of heparin and a low molecular weight
heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise. Thromb Haemost. 1992;68(5):550-5.

73. de Boer A, Kluft C, Gerloff J, Dooijewaard G, Gunzler WA, Beier H, et al. Pharmacokinetics of saruplase, a recombinant
unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in
healthy male subjects. Thromb Haemost. 1993;70(2):320-5.

74. De Boer A, Kluft C, Kasper FJ, Kroon JM, Schoemaker HC, Breimer DD, et al. Interaction study between nifedipine and
recombinant tissue-type plasminogen activator in healthy subjects. Br J Clin Pharmacol. 1993;36(2):99-104.

75. de Boer A, Kluft C, Kroon JM, Kasper FJ, Schoemaker HC, Pruis J, et al. Liver blood flow as a major determinant of the
clearance of recombinant human tissue-type plasminogen activator. Thromb Haemost. 1992;67(1):83-7.

76. de Boer A, Kroon JM, Kroon C, van Vliet A, Schoemaker HC, Breimer DD, et al. Pronounced effects of the combination of a
new thromboxane antagonist (GR32191) and heparin on bleeding time in man. Thromb Haemost. 1992;68(1):24-9.

77. de Boer A, Stiekema JC, Danhof M, van Dinther TG, Boeijinga JK, Cohen AF, et al. Studies of interaction of a low-molecular-
weight heparinoid (Org 10172) with cloxacillin and ticarcillin in healthy male volunteers. Antimicrob Agents Chemother.
1991;35(10):2110-5.

78. de Haas SL, de Visser SJ, van der Post JP, de Smet M, Schoemaker RC, Rijnbeek B, et al. Pharmacodynamic and
pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy
volunteers. J Psychopharmacol. 2007;21(4):374-83.

79. de Haas SL, de Visser SJ, van der Post JP, Schoemaker RC, van Dyck K, Murphy MG, et al. Pharmacodynamic and
pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male
volunteers. J Psychopharmacol. 2008;22(1):24-32.

80. de Haas SL, Franson KL, Schmitt JA, Cohen AF, Fau JB, Dubruc C, et al. The pharmacokinetic and pharmacodynamic effects of
SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J Psychopharmacol.
2009;23(6):625-32.

81. de Haas SL, Schoemaker RC, van Gerven JM, Hoever P, Cohen AF, Dingemanse J. Pharmacokinetics, pharmacodynamics and
the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol. 2010;24(11):1619-29.

82. de Haas SL, Zoethout RW, Van Dyck K, De Smet M, Rosen LB, Murphy MG, et al. The effects of TPA023, a GABAAalpha2,3
subtype-selective partial agonist, on essential tremor in comparison to alcohol. J Psychopharmacol. 2012;26(2):282-91.

83. de Roode A, van Gerven JM, Schoemaker RC, Engbers FH, Olieman W, Kroon JR, et al. A comparison of the effects of propofol
and midazolam on memory during two levels of sedation by using target-controlled infusion. Anesth Analg. 2000;91(5):1056-61.

84. de Visser SJ, Uchida N, van Vliet-Daskalopoulou E, Fukazawa I, van Doorn MB, van den Heuvel MW, et al. Pharmacokinetic
differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659
and EE). Contraception. 2003;68(3):195-202.

85. de Visser SJ, van der Post J, Pieters MS, Cohen AF, van Gerven JM. Biomarkers for the effects of antipsychotic drugs in healthy
volunteers. Br J Clin Pharmacol. 2001;51(2):119-32.

86. de Visser SJ, van der Post JP, de Waal PP, Cornet F, Cohen AF, van Gerven JM. Biomarkers for the effects of benzodiazepines
in healthy volunteers. Br J Clin Pharmacol. 2003;55(1):39-50.

87. de Visser SJ, van der Post JP, Nanhekhan L, Schoemaker RC, Cohen AF, van Gerven JM. Concentration-effect relationships of
two rilmenidine single-dose infusion rates in hypertensive patients. Clin Pharmacol Ther. 2002;72(4):419-28.

88. de Visser SJ, van Gerven JM, Schoemaker RC, Cohen AF. Concentration-effect relationships of two infusion rates of the
imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects. Br J Clin Pharmacol.
2001;51(5):423-8.

89. den Hartigh J, Hilders CG, Schoemaker RC, Hulshof JH, Cohen AF, Vermeij P. Tinnitus suppression by intravenous lidocaine in
relation to its plasma concentration. Clin Pharmacol Ther. 1993;54(4):415-20.

90. Dijkstra FM, Jacobs GE, Cohen AF. Question-based Drug Development for psilocybin. Lancet Psychiatry. 2016;3(9):806-7.

91. Dingemanse J, van Gerven JM, Schoemaker RC, Roncari G, Oberye JJ, van Oostenbruggen MF, et al. Integrated
pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration
to healthy male subjects. Br J Clin Pharmacol. 1997;44(5):477-86.

92. Dooijewaard G, de Boer A, Turion PN, Cohen AF, Breimer DD, Kluft C. Physical exercise induces enhancement of urokinase-
type plasminogen activator (u-PA) levels in plasma. Thromb Haemost. 1991;65(1):82-6.

93. Dubois EA, Cohen AF. Dabigatran etexilate. Br J Clin Pharmacol. 2010;70(1):14-5.

94. Dubois EA, Cohen AF. Icatibant. Br J Clin Pharmacol. 2010;69(5):425-6.

95. Dubois EA, Cohen AF. Sapropterin. Br J Clin Pharmacol. 2010;69(6):576-7.

96. Dubois EA, Cohen AF. Retapamulin. Br J Clin Pharmacol. 2010;69(1):2-3.

97. Dubois EA, Cohen AF. Aliskiren. Br J Clin Pharmacol. 2009;68(5):653-4.

98. Dubois EA, Cohen AF. Maraviroc and raltegravir. Br J Clin Pharmacol. 2009;68(5):651-2.

99. Dubois EA, Cohen AF. Panitumumab. Br J Clin Pharmacol. 2009;68(4):482-3.

100. Dubois EA, Cohen AF. Abatacept. Br J Clin Pharmacol. 2009;68(4):480-1.

101. Dubois EA, Cohen AF. Trabectedin. Br J Clin Pharmacol. 2009;68(3):320-1.

102. Dubois EA, Cohen AF. Eculizumab. Br J Clin Pharmacol. 2009;68(3):318-9.

103. Dubois EA, Franson KL, van Gerven JM, Bolk JH, Cohen AF. [Integration of training in pharmacology and pharmacotherapy in
the medical curriculum in Leiden, the Netherlands]. Ned Tijdschr Geneeskd. 2004;148(4):194-9.

104. Dubois EA, Rissmann R, Cohen AF. Tolvaptan. Br J Clin Pharmacol. 2012;73(1):9-11.

105. Dubois EA, Rissmann R, Cohen AF. Denosumab. Br J Clin Pharmacol. 2011;71(6):804-6.

106. Dubois EA, Rissmann R, Cohen AF. Rilonacept and canakinumab. Br J Clin Pharmacol. 2011;71(5):639-41.

107. Dumont GJ, de Visser SJ, Cohen AF, van Gerven JM, Biomarker Working Group of the German Association for Applied Human
P. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Br J Clin Pharmacol. 2005;59(5):495-

108. Eddleston M, Cohen AF, Webb DJ. Implications of the BIA-102474-101 study for review of first-into-human clinical trials. Br J
Clin Pharmacol. 2016;81(4):582-6.

109. Faaij RA, Burggraaf J, Schoemaker RC, de Greef R, Cohen AF. The synthetic pentasaccharide fondaparinux sodium does not
interact with oral warfarin. Clin Pharmacokinet. 2002;41 Suppl 2:27-9.

110. Faaij RA, Burggraaf J, Schoemaker RC, Van Amsterdam RG, Cohen AF. Absence of an interaction between the synthetic
pentasaccharide fondaparinux and oral warfarin. Br J Clin Pharmacol. 2002;54(3):304-8.

111. Faaij RA, Srivastava N, van Griensven JM, Schoemaker RC, Kluft C, Burggraaf J, et al. The oral bioavailability of pentosan
polysulphate sodium in healthy volunteers. Eur J Clin Pharmacol. 1999;54(12):929-35.

112. Faaij RA, Van Gerven JM, Jolivet-Landreau I, Masclee AA, Vendrig EM, Schoemaker RC, et al. Onset of action during on-
demand treatment with maalox suspension or low-dose ranitidine for heartburn. Aliment Pharmacol Ther. 1999;13(12):1605-10.

113. Faaij RA, van Griensven JM, Schoemaker RC, Goggin T, Guenzi A, Kroon JM, et al. The effect of warfarin on the
pharmacokinetics and pharmacodynamics of napsagatran in healthy male volunteers. Eur J Clin Pharmacol. 2001;57(1):25-9.

114. Ferro A, Loke YK, Lewis LD, Somogyi A, Cohen AF, Ritter JM. Editors’ pick 2013. Br J Clin Pharmacol. 2014;77(2):228-32.

115. Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N, Kamerling IM, et al. Efficacy and safety of RPL554, a dual PDE3
and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical
trials. Lancet Respir Med. 2013;1(9):714-27.

116. Franson KL, Cohen AF. How it works. Br J Clin Pharmacol. 2009;68(3):315-7.

117. Franson KL, Dubois EA, de Kam ML, Burggraaf J, Cohen AF. Creating a culture of thoughtful prescribing. Med Teach.
2009;31(5):415-9.

118. Franson KL, Dubois EA, de Kam ML, Cohen AF. Measuring learning from the TRC pharmacology E-Learning program. Br J
Clin Pharmacol. 2008;66(1):135-41.

119. Franson KL, Dubois EA, van Gerven JM, Cohen AF. Development of visual pharmacology education across an integrated
medical school curriculum. J Vis Commun Med. 2007;30(4):156-61.

120. Ganteris-Gerritsen E, Ugahary LC, Jansen J, Mulder PG, Cohen AF, van Meurs JC. Six months treatment with ibopamine in
patients with hypotony after vitreoretinal surgery for retinal detachment, uveitis or penetrating trauma. Retina. 2012;32(4):742-7.

121. Geerts BF, van Dongen MG, Flameling B, Moerland MM, de Kam ML, Cohen AF, et al. Hydrolyzed casein decreases
postprandial glucose concentrations in T2DM patients irrespective of leucine content. J Diet Suppl. 2011;8(3):280-92.

122. Gijsman HJ, Cohen AF, van Gerven JM. The application of the principles of clinical drug development to pharmacological
challenge tests of the serotonergic system. J Psychopharmacol. 2004;18(1):7-13.

123. Gijsman HJ, van Gerven JM, de Kam ML, Schoemaker RC, Pieters MS, Weemaes M, et al. Placebo-controlled comparison of
three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers. J Clin Psychopharmacol. 2002;22(2):183-9.

124. Gijsman HJ, Van Gerven JM, Tieleman MC, Schoemaker RC, Pieters MS, Ferrari MD, et al. Pharmacokinetic and
pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. J Clin Psychopharmacol.
1998;18(4):289-95.

125. Gijsman HJ, van Gerven JM, Verkes RJ, Schoemaker RC, Pieters MS, Pennings EJ, et al. Saccadic peak velocity and EEG as
end-points for a serotonergic challenge test. Hum Psychopharmacol. 2002;17(2):83-9.

126. Gijsman HJ, Verkes RJ, van Gerven JM, Cohen AF. MDMA study. Neuropsychopharmacology. 1999;21(4):597.

127. Gilchrist A, Loke YK, Somogyi AA, Cohen AF, Ritter JM. BJCP 40th anniversary: moving forward, looking back. Br J Clin
Pharmacol. 2014;78(6):1175-84.

128. Goulooze SC, Cohen AF, Rissmann R. Olaparib. Br J Clin Pharmacol. 2016;81(1):171-3.

129. Goulooze SC, Cohen AF, Rissmann R. Mirabegron. Br J Clin Pharmacol. 2015;80(4):762-4.

130. Goulooze SC, Cohen AF, Rissmann R. Bedaquiline. Br J Clin Pharmacol. 2015;80(2):182-4.

131. Goulooze SC, Cohen AF, Rissmann R. Lomitapide. Br J Clin Pharmacol. 2015;80(2):179-81.

132. Goulooze SC, Franson KL, Cohen AF, Rissmann R. Clinical Pharmacology Research Internships at the Interface between
Academia and Industry: Students’ Perceptions and Scientific Output. Basic Clin Pharmacol Toxicol. 2017;121(1):22-8.

133. Hamilton MJ, Cohen AF, Yuen AW, Harkin N, Land G, Weatherley BC, et al. Carbamazepine and lamotrigine in healthy
volunteers: relevance to early tolerance and clinical trial dosage. Epilepsia. 1993;34(1):166-73.

134. Hartnick CJ, Cohen AF, Smith RV. Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3
(muromonab-CD3). Ann Otol Rhinol Laryngol. 1997;106(8):640-2.

135. Hessel MH, Cohen AF, Rissmann R. Sofosbuvir and daclatasvir. Br J Clin Pharmacol. 2016;82(3):878-9.

136. Heuberger J, Rotmans JI, Gal P, Stuurman FE, Daniels JMA, de Kam ML, et al. Erythropoietin on cycling performance –
Authors’ reply. Lancet Haematol. 2017;4(10):e462-e4.

137. Heuberger J, Rotmans JI, Gal P, Stuurman FE, van ‘t Westende J, Post TE, et al. Effects of erythropoietin on cycling performance
of well trained cyclists: a double-blind, randomised, placebo-controlled trial. Lancet Haematol. 2017;4(8):e374-e86.

138. Heuberger J, van Dijkman SC, Cohen AF. Futility of current urine salbutamol doping control. Br J Clin Pharmacol.
2018;84(8):1830-8.

139. Heuberger JA, Cohen AF. World-class cyclists on erythropoietin. Br J Clin Pharmacol. 2014;77(3):582.

140. Heuberger JA, Cohen Tervaert JM, Schepers FM, Vliegenthart AD, Rotmans JI, Daniels JM, et al. Erythropoietin doping in
cycling: lack of evidence for efficacy and a negative risk-benefit. Br J Clin Pharmacol. 2013;75(6):1406-21.

141. Heuberger JA, Guan Z, Oyetayo OO, Klumpers L, Morrison PD, Beumer TL, et al. Population pharmacokinetic model of THC
integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics. Clin Pharmacokinet.
2015;54(2):209-19.

142. Hollander AA, van der Woude FJ, Cohen AF. Effect of grapefruit juice on blood cyclosporin concentration. Lancet.
1995;346(8967):123; author reply -4.

143. Hollander AA, van Rooij J, Lentjes GW, Arbouw F, van Bree JB, Schoemaker RC, et al. The effect of grapefruit juice on
cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther. 1995;57(3):318-24.

144. Hoogstins CE, Tummers QR, Gaarenstroom KN, de Kroon CD, Trimbos JB, Bosse T, et al. A Novel Tumor-Specific Agent for
Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer. Clin
Cancer Res. 2016;22(12):2929-38.

145. Huizinga CRH, de Kam ML, Stockmann H, van Gerven JMA, Cohen AF, van der Bogt KEA. Evaluating Fitness to Perform in
Surgical Residents after Night Shifts and Alcohol Intoxication: The development of a “Fit-to-Perform” test. J Surg Educ. 2018;75(4):968-77.

146. Jacobs GE, der Grond J, Teeuwisse WM, Langeveld TJ, van Pelt J, Verhagen JC, et al. Hypothalamic glutamate levels following
serotonergic stimulation: a pilot study using 7-Tesla magnetic resonance spectroscopy in healthy volunteers. Prog Neuropsychopharmacol
Biol Psychiatry. 2010;34(3):486-91.

147. Kamerling IM, Burggraaf J, van Haarst AD, Oppenhuizen-Duinker MF, Schoemaker HC, Biemond I, et al. The effect of motilin
on the rectum in healthy volunteers. Br J Clin Pharmacol. 2003;55(6):538-43.

148. Kamerling IM, van Haarst AD, Burggraaf J, de Kam M, Biemond I, Jones R, et al. Exogenous motilin affects postprandial
proximal gastric motor function and visceral sensation. Dig Dis Sci. 2002;47(8):1732-6.

149. Kamerling IM, Van Haarst AD, Burggraaf J, Schoemaker HC, Biemond I, Jones R, et al. Dose-related effects of motilin on
proximal gastrointestinal motility. Aliment Pharmacol Ther. 2002;16(1):129-35.

150. Kamerling IM, Van Haarst AD, Burggraaf J, Schoemaker RC, Biemond I, Heinzerling H, et al. Motilin effects on the proximal
stomach in patients with functional dyspepsia and healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2003;284(5):G776-81.

151. Kamerling IM, van Haarst AD, Burggraaf J, Schoemaker RC, de Kam ML, Heinzerling H, et al. Effects of a nonpeptide motilin
receptor antagonist on proximal gastric motor function. Br J Clin Pharmacol. 2004;57(4):393-401.

152. Kamerling IM, Van Haarst AD, De Kam ML, Cohen AF, Masclee AA, Burggraaf J. Gallbladder volume as a biomarker for the
motilin effect in healthy volunteers and patients with functional dyspepsia. Aliment Pharmacol Ther. 2004;19(7):797-804.

153. Kanhai K, Goulooze SC, Stevens J, Hay JL, Dent G, Verma A, et al. Quantifying Beta-Galactosylceramide Kinetics in
Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling. Clin Transl Sci. 2016;9(6):321-7.

154. Karlsson MO, Schoemaker RC, Kemp B, Cohen AF, van Gerven JM, Tuk B, et al. A pharmacodynamic Markov mixed-effects
model for the effect of temazepam on sleep. Clin Pharmacol Ther. 2000;68(2):175-88.

155. Kars ME, Pijl H, Cohen AF, Frolich M, Schoemaker HC, Brandenburg HC, et al. Specific stimulation of brain serotonin
mediated neurotransmission by dexfenfluramine does not restore growth hormone responsiveness in obese women. Clin Endocrinol (Oxf).
1996;44(5):541-6.

156. Kemme MJ, Burggraaf J, Schoemaker RC, Cohen AF. No Influence of acute hypertriglyceridemia on plasma t-PA in healthy
male volunteers. Thromb Res. 2001;103(1):9-16.

157. Kemme MJ, Burggraaf J, Schoemaker RC, Cohen AF, Blauw GJ. No evidence for functional involvement of 5-HT2B receptors
in serotonin-induced vasodilatation in the human forearm. J Cardiovasc Pharmacol. 2000;36(6):699-703.

158. Kemme MJ, Burggraaf J, Schoemaker RC, Cohen AF, Kluft C, Chia S, et al. Local tissue factor pathway inhibitor release in the
human forearm. Thromb Haemost. 2003;89(3):438-45.

159. Kemme MJ, Burggraaf J, Schoemaker RC, Kluft C, Cohen AF. Quantification of heparin-induced TFPI release: a maximum
release at low heparin dose. Br J Clin Pharmacol. 2002;54(6):627-34.

160. Kemme MJ, Burggraaf J, Schoemaker RC, Paulson S, Karim A, Lentjes EG, et al. The influence of reduced liver blood flow on
the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor. Clin Pharmacol Ther. 2000;67(5):504-11.

161. Kemme MJ, Faaij RA, Schoemaker RC, Kluft C, Meijer P, Cohen AF, et al. Disagreement between bedside and laboratory
activated partial thromboplastin time and international normalized ratio for various novel anticoagulants. Blood Coagul Fibrinolysis.
2001;12(7):583-91.

162. Kemme MJ, Schoemaker RC, Burggraaf J, van der Linden M, Noordzij M, Moerland M, et al. Endothelial binding of
recombinant tissue plasminogen activator: quantification in vivo using a recirculatory model. J Pharmacokinet Pharmacodyn. 2003;30(1):3-

163. Kemme MJ, vd Post JP, Schoemaker RC, Straub M, Cohen AF, van Gerven JM. Central nervous system effects of moxonidine
experimental sustained release formulation in patients with mild to moderate essential hypertension. Br J Clin Pharmacol. 2003;55(6):518-
25.

164. Kenter MJ, Cohen AF. The return of the prodigal son and the extraordinary development route of antibody TGN1412 – lessons
for drug development and clinical pharmacology. Br J Clin Pharmacol. 2015;79(4):545-7.

165. Kenter MJ, Cohen AF. Re-engineering the European Union Clinical Trials Directive. Lancet. 2012;379(9828):1765-7.

166. Kenter MJ, Cohen AF. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet.
2006;368(9544):1387-91.

167. Klein RH, Alvarez-Jimenez R, Sukhai RN, Oostdijk W, Bakker B, Reeser HM, et al. Pharmacokinetics and pharmacodynamics
of orally administered clonidine: a model-based approach. Horm Res Paediatr. 2013;79(5):300-9.

168. Koster RW, Cohen AF, Hopkins GR, Beier H, Gunzler WA, van der Wouw PA. Pharmacokinetics and pharmacodynamics of
saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb
Haemost. 1994;72(5):740-4.

169. Koster RW, Cohen AF, Kluft C, Kasper FJ, van der Wouw PA, Weatherley BC. The pharmacokinetics of recombinant double-
chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction. Clin
Pharmacol Ther. 1991;50(3):267-77.

170. Kreilgaard M, Kemme MJ, Burggraaf J, Schoemaker RC, Cohen AF. Influence of a microemulsion vehicle on cutaneous
bioequivalence of a lipophilic model drug assessed by microdialysis and pharmacodynamics. Pharm Res. 2001;18(5):593-9.

171. Kroon C, Cohen AF. Serious intercurrent disease in healthy volunteers in clinical pharmacological research. Lancet.
1992;339(8791):504.

172. Kroon C, de Boer A, Hoogkamer JF, Schoemaker HC, van der Meer EJ, Edelbroek PM, et al. Detection of drug interactions with
single dose acenocoumarol: new screening method? Int J Clin Pharmacol Ther Toxicol. 1990;28(8):355-60.

173. Kroon C, de Boer A, Kroon JM, Schoemaker HC, van den Meer FJ, Cohen AF. Influence of skinfold thickness on heparin
absorption. Lancet. 1991;337(8747):945-6.

174. Kroon C, ten Hove WR, de Boer A, Kroon JM, van der Pol JM, Harthoorn-Lasthuizen EJ, et al. Highly variable anticoagulant
response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers.
Circulation. 1992;86(5):1370-5.

175. Krulder JW, de Boer A, van den Besselaar AM, Cohen AF, Schoemaker HC, Briet E, et al. Diurnal rhythm in anticoagulant
effect of heparin during a low dose constant rate infusion. A study in healthy volunteers. Thromb Haemost. 1992;68(1):30-2.

176. Langendonk JG, Meinders AE, Burggraaf J, Frolich M, Roelen CA, Schoemaker RC, et al. Influence of obesity and body fat
distribution on growth hormone kinetics in humans. Am J Physiol. 1999;277(5):E824-9.

177. Langendonk JG, Pijl H, Toornvliet AC, Burggraaf J, Frolich M, Schoemaker RC, et al. Circadian rhythm of plasma leptin levels
in upper and lower body obese women: influence of body fat distribution and weight loss. J Clin Endocrinol Metab. 1998;83(5):1706-12.

178. Langendonk JG, Veldhuis JD, Burggraaf J, Schoemaker RC, Cohen AF, Meinders AE, et al. Estimation of growth hormone
secretion rate: impact of kinetic assumptions intrinsic to the analytical approach. Am J Physiol Regul Integr Comp Physiol.
2001;280(1):R225-32.

179. Leebeek FW, Kluft C, Knot EA, Los P, Cohen AF, Six AJ. Plasmin inhibitors in the prevention of systemic effects during
thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin. J Am Coll Cardiol. 1990;15(6):1212-20.

180. Levin RJ, Henick DH, Cohen AF. Human immunodeficiency virus–associated non-Hodgkin’s lymphoma presenting as an
auricular perichondritis. Otolaryngol Head Neck Surg. 1995;112(3):493-5.

181. Lewis LD, Somogyi A, Loke YK, Ferro A, Cohen AF, Ritter JM. Editors’ pick 2012. Br J Clin Pharmacol. 2013;75(1):1-6.

182. Liem-Moolenaar M, Cerneus D, Molloy CJ, End D, Brown KH, de Kam ML, et al. Pharmacodynamics and pharmacokinetics of
the novel thrombopoietin mimetic peptide RWJ-800088 in humans. Clin Pharmacol Ther. 2008;84(4):481-7.

183. Liem-Moolenaar M, Gray FA, de Visser SJ, Franson KL, Schoemaker RC, Schmitt JA, et al. Psychomotor and cognitive effects
of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol. J Psychopharmacol.
2010;24(1):73-82.

184. Liem-Moolenaar M, Peeters P, Kamerling IM, Hogg C, Holder G, Kleijn HJ, et al. Early stage development of the glycine-1 re-
uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men. Br J Clin Pharmacol. 2013;75(6):1455-

185. Liem-Moolenaar M, Rad M, Zamuner S, Cohen AF, Lemme F, Franson KL, et al. Central nervous system effects of the
interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men. Br J Clin Pharmacol.
2011;71(6):907-16.

186. Liem-Moolenaar M, Zoethout RW, de Boer P, Schmidt M, de Kam ML, Cohen AF, et al. The effects of the glycine reuptake
inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in

healthy subjects. J Psychopharmacol. 2010;24(11):1671-9.

187. Liem-Moolenaar M, Zoethout RW, de Boer P, Schmidt M, de Kam ML, Cohen AF, et al. The effects of a glycine reuptake
inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in
healthy subjects. J Psychopharmacol. 2010;24(11):1681-7.

188. Loke YK, Ferro A, Lewis LD, Cohen AF, Somogyi A, Ritter JM. Editors’ pick 2010. Br J Clin Pharmacol. 2011;71(1):3-6.

189. Loke YK, Somogyi A, Lewis LD, Schachter M, Cohen AF, Ritter JM. Looking back: editors’ pick of 2008. Br J Clin Pharmacol.
2009;67(1):1-4.

190. Lycklama a Nijeholt GJ, Burggraaf K, Wasser MN, Schultze Kool LJ, Schoemaker RC, Cohen AF, et al. Variability of
splanchnic blood flow measurements using MR velocity mapping under fasting and post-prandial conditions–comparison with echo-
Doppler. J Hepatol. 1997;26(2):298-304.

191. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of
the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol
Ther. 1992;51(6):715-28.

192. Milgrim LM, Cohen AF. Nonpulmonary sinonasal sarcoidosis with intracranial invasion. Otolaryngol Head Neck Surg.
1996;114(1):162-5.

193. Milgrim LM, Lawson W, Cohen AF. Anthropometric analysis of the female Latino nose. Revised aesthetic concepts and their
surgical implications. Arch Otolaryngol Head Neck Surg. 1996;122(10):1079-86.

194. Moors EHM, Cohen AF, Schellekens H. Towards a sustainable system of drug development. Drug Discov Today.
2014;19(11):1711-20.

195. Mulders TM, Venizelos V, Schoemaker R, Cohen AF, Breimer DD, Mulder GJ. Characterization of glutathione conjugation in
humans: stereoselectivity in plasma elimination pharmacokinetics and urinary excretion of (R)- and (S)-2-bromoisovalerylurea in healthy
volunteers. Clin Pharmacol Ther. 1993;53(1):49-58.

196. Myssiorek D, Cohen AF. Coaxial frontal sinus drainage catheter. Laryngoscope. 1989;99(3):342-3.

197. Ollier C, Faaij RA, Santoni A, Duvauchelle T, van Haard PM, Schoemaker RC, et al. Absence of interaction of fondaparinux
sodium with aspirin and piroxicam in healthy male volunteers. Clin Pharmacokinet. 2002;41 Suppl 2:31-7.

 

198. Pieters MS, Jennekens-Schinkel A, Schoemaker HC, Cohen AF. Self-selection for personality variables among healthy
volunteers. Br J Clin Pharmacol. 1992;33(1):101-6.

199. Pieters MS, van Steveninck AF, Schoemaker RC, Kroon JM, van Gerven JM, Cohen AF. The psychomotor effects of
carbamazepine in epileptic patients and healthy volunteers. J Psychopharmacol. 2003;17(3):269-72.

200. Pijl H, Cohen AF, Verkes RJ, Koppeschaar HP, Iestra JA, Schoemaker HC, et al. Plasma amino acid ratios related to brain
serotonin synthesis in response to food intake in bulimia nervosa. Biol Psychiatry. 1995;38(10):659-68.

201. Pijl H, de Meijer PH, Langius J, Coenegracht CI, van den Berk AH, Chandie Shaw PK, et al. Food choice in hyperthyroidism:
potential influence of the autonomic nervous system and brain serotonin precursor availability. J Clin Endocrinol Metab. 2001;86(12):5848-

202. Pijl H, Koppeschaar HP, Cohen AF, Iestra JA, Schoemaker HC, Frolich M, et al. Evidence for brain serotonin-mediated control
of carbohydrate consumption in normal weight and obese humans. Int J Obes Relat Metab Disord. 1993;17(9):513-20.

203. Pijl H, Langendonk JG, Burggraaf J, Frolich M, Cohen AF, Veldhuis JD, et al. Altered neuroregulation of GH secretion in
viscerally obese premenopausal women. J Clin Endocrinol Metab. 2001;86(11):5509-15.

204. Posner J, Cohen AF, Land G, Winton C, Peck AW. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with
unconjugated hyperbilirubinaemia (Gilbert’s syndrome). Br J Clin Pharmacol. 1989;28(1):117-20.

205. Rad M, Burggraaf J, de Kam ML, Cohen AF, Kluft C. Discriminant analysis of the metabolic effects of a new combined
contraceptive vaginal ring containing Nestorone/EE vs. a second-generation oral contraceptive containing levonorgestrel/EE. Contraception.
2012;86(3):231-7.

206. Rad M, Burggraaf J, Sitruk-Ware RL, de Kam ML, Cohen AF, Kluft C. Increased impact of a contraceptive vaginal ring with
ethinyl estradiol and nestorone on C-reactive protein. Steroids. 2012;77(13):1483-6.

207. Rad M, Humpel M, Schaefer O, Schoemaker RC, Schleuning WD, Cohen AF, et al. Pharmacokinetics and systemic endocrine
effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women. Br J Clin Pharmacol. 2006;62(3):288-

208. Rad M, Kluft C, de Kam ML, Meijer P, Cohen AF, Grubb GS, et al. Metabolic profile of a continuous versus a cyclic low-dose
combined oral contraceptive after one year of use. Eur J Contracept Reprod Health Care. 2011;16(2):85-94.

209. Rijnbeek B, de Visser SJ, Franson KL, Cohen AF, van Gerven JM. REM sleep effects as a biomarker for the effects of
antidepressants in healthy volunteers. J Psychopharmacol. 2003;17(2):196-203.

210. Rissmann R, Dubois EA, Franson KL, Cohen AF. Concept-based learning of personalized prescribing. Br J Clin Pharmacol.
2012;74(4):589-96.

211. Rissmann R, Hessel MH, Cohen AF. Vemurafenib/dabrafenib and trametinib. Br J Clin Pharmacol. 2015;80(4):765-7.

212. Ruys-Dudok van Heel I, Cohen AF, Wit JM, van der Heijden AJ, van den Anker JN, van Meurs AH. [Clinical drug research in
children: current international guidelines. Committee for Proprietary Medicinal Products]. Ned Tijdschr Geneeskd. 1998;142(1):6-9.

213. Schoemaker RC, Buijs MM, Pijl H, Burggraaf J, Cohen AF. Modeling the influence of growth hormone on lipolysis. J
Pharmacokinet Pharmacodyn. 2002;29(2):157-70.

214. Schoemaker RC, Burggraaf J, Cohen AF. Assessment of hepatic blood flow using continuous infusion of high clearance drugs.
Br J Clin Pharmacol. 1998;45(5):463-9.

215. Schoemaker RC, Cohen AF. Estimating impossible curves using NONMEM. Br J Clin Pharmacol. 1996;42(3):283-90.

216. Schoemaker RC, van dDer Vorst MM, van Heel IR, Cohen AF, Burggraaf J, Pediatric Pharmacology N. Development of an
optimal furosemide infusion strategy in infants with modeling and simulation. Clin Pharmacol Ther. 2002;72(4):383-90.

217. Schoemaker RC, van Gerven JM, Cohen AF. Estimating potency for the Emax-model without attaining maximal effects. J
Pharmacokinet Biopharm. 1998;26(5):581-93.

218. Somogyi A, Loke YK, Ferro A, Lewis LD, Cohen AF, Ritter JM. Clinical pharmacology: a declaration of intent. Br J Clin
Pharmacol. 2010;70(1):1-2.

219. Somogyi A, Loke YK, Ferro A, Lewis LD, Cohen AF, Ritter JM. Editors’ pick 2009. Br J Clin Pharmacol. 2010;69(2):107-10.

220. Somogyi AA, Lewis LD, Cohen AF, Flockhart DA, Ferro A, Loke YK, et al. Editors’ report, November 2013. Br J Clin
Pharmacol. 2014;77(3):401-2.

221. Soons PA, Cohen AF, Breimer DD. Comparative effects of felodipine, nitrendipine and nifedipine in healthy subjects:
concentration-effect relationships of racemic drugs and enantiomers. Eur J Clin Pharmacol. 1993;44(2):113-20.

222. Soons PA, De Boer A, Cohen AF, Breimer DD. Assessment of hepatic blood flow in healthy subjects by continuous infusion of
indocyanine green. Br J Clin Pharmacol. 1991;32(6):697-704.

223. Soons PA, Mulders TM, Uchida E, Schoemaker HC, Cohen AF, Breimer DD. Stereoselective pharmacokinetics of oral
felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics. Eur J Clin Pharmacol. 1993;44(2):163-9.

224. Soons PA, Schoemaker HC, Cohen AF, Breimer DD. Intraindividual variability in nifedipine pharmacokinetics and effects in
healthy subjects. J Clin Pharmacol. 1992;32(4):324-31.

225. Soons PA, Vogels BA, Roosemalen MC, Schoemaker HC, Uchida E, Edgar B, et al. Grapefruit juice and cimetidine inhibit
stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther. 1991;50(4):394-403.

226. Stiekema JC, Van Griensven JM, Van Dinther TG, Cohen AF. A cross-over comparison of the anti-clotting effects of three low
molecular weight heparins and glycosaminoglycuronan. Br J Clin Pharmacol. 1993;36(1):51-6.

227. Strougo A, Zuurman L, Roy C, Pinquier JL, van Gerven JM, Cohen AF, et al. Modelling of the concentration–effect relationship
of THC on central nervous system parameters and heart rate — insight into its mechanisms of action and a tool for clinical research and
development of cannabinoids. J Psychopharmacol. 2008;22(7):717-26.

228. te Beek ET, de Boer P, Moerland M, Schmidt ME, Hoetjes NJ, Windhorst AD, et al. In vivo quantification of striatal dopamine
D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography. J Psychopharmacol. 2012;26(8):1128-

229. te Beek ET, Moerland M, de Boer P, van Nueten L, de Kam ML, Burggraaf J, et al. Pharmacokinetics and central nervous system
effects of the novel dopamine D2 receptor antagonist JNJ-37822681. J Psychopharmacol. 2012;26(8):1119-27.

230. Teitelbaum Z, Lave T, Freijer J, Cohen AF. Risk assessment in extrapolation of pharmacokinetics from preclinical data to
humans. Clin Pharmacokinet. 2010;49(9):619-32.

231. Tijssen MA, Schoemaker HC, Edelbroek PJ, Roos RA, Cohen AF, van Dijk JG. The effects of clonazepam and vigabatrin in
hyperekplexia. J Neurol Sci. 1997;149(1):63-7.

232. Timmer CJ, Srivastava N, Dieben TO, Cohen AF. Bioavailability and bioequivalence of etonogestrel from two oral formulations
of desogestrel: Cerazette and Liseta. Eur J Drug Metab Pharmacokinet. 1999;24(4):335-43.

233. Tuk B, Oberye JJ, Pieters MS, Schoemaker RC, Kemp B, van Gerven J, et al. Pharmacodynamics of temazepam in primary
insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep.
Clin Pharmacol Ther. 1997;62(4):444-52.

234. Tummers QR, Hoogstins CE, Gaarenstroom KN, de Kroon CD, van Poelgeest MI, Vuyk J, et al. Intraoperative imaging of folate
receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17. Oncotarget. 2016;7(22):32144-55.

235. Twiss IM, Burggraaf J, Schoemaker RC, van Elburg RM, den Hartigh J, Cohen AF, et al. The sugar absorption test in the
evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate. Clin Pharmacol Ther. 2001;69(6):431-7.

236. Twiss IM, van den Berk AH, de Kam ML, Bosch JJ, Cohen AF, Vermeij P, et al. A comparison of the gastrointestinal effects of
the nitrogen-containing bisphosphonates pamidronate, alendronate, and olpadronate in humans. J Clin Pharmacol. 2006;46(4):483-7.

237. van Bronswijk H, Dubois EA, Osanto S, Cohen AF. [New drugs; sunitinib and sorafenib]. Ned Tijdschr Geneeskd.
2007;151(52):2888-90.

238. van Bronswijk H, Dubois EA, Pijl H, Cohen AF. [New drugs; exenatide and sitagliptin]. Ned Tijdschr Geneeskd.
2008;152(15):876-9.

239. van Bronswijk H, Dubois EA, Pijl H, Cohen AF. [New drugs; rimonabant]. Ned Tijdschr Geneeskd. 2007;151(47):2620-2.

240. van Bronswijk H, Dubois EA, van Dissel JT, Cohen AF. [New drugs; daptomycin]. Ned Tijdschr Geneeskd. 2007;151(50):2777-

241. van Bronswijk H, Dubois EA, van Gerven JM, Cohen AF. [New drugs; natalizumab]. Ned Tijdschr Geneeskd. 2008;152(9):499-

242. van Bronswijk H, Dubois EA, van Meurs JC, Cohen AF. [New drugs; pegaptanib and ranibizumab]. Ned Tijdschr Geneeskd.
2008;152(2):82-4.

243. van Bronswijk H, Dubois EA, Zitman FG, Cohen AF. [New drugs; varenicline]. Ned Tijdschr Geneeskd. 2007;151(45):2503-4.

244. van Bronswijk P, Cohen AF. The first recordings of pharmacological effects. Br J Clin Pharmacol. 2008;66(5):588-93.

245. van den Berg G, van Steveninck F, Gubbens-Stibbe JM, Schoemaker HC, de Boer AG, Cohen AF. Influence of food on the
bioavailability of metoprolol from an OROS system; a study in healthy volunteers. Eur J Clin Pharmacol. 1990;39(3):315-6.

246. Van den Bogert CA, Cohen AF. Need for a proactive and structured approach to risk analysis when designing phase I trials.
BMJ. 2015;351:h3899.

247. van den Bogert CA, Cohen AF, Leufkens HGM, van Gerven JMA. Pharmacological vs. classical approaches in the design of first
in man clinical drug trials. Br J Clin Pharmacol. 2017;83(12):2807-12.

248. van den Heuvel TW, Cohen AF, Rissmann R. European drug market entries 2015 with new mechanisms of action. Clin Med
(Lond). 2016;16(5):475-80.

249. van der Pijl JW, Srivastava N, Denouel J, Burggraaf J, Schoemaker RC, van der Woude FJ, et al. Pharmacokinetics of the
conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis. Transplantation.

1996;62(4):456-62.

250. van der Post J, de Waal PP, de Kam ML, Cohen AF, van Gerven JM. No evidence of the usefulness of eye blinking as a marker
for central dopaminergic activity. J Psychopharmacol. 2004;18(1):109-14.

251. van der Post J, Noordzij LA, de Kam ML, Blauw GJ, Cohen AF, van Gerven JM. Evaluation of tests of central nervous system
performance after hypoxemia for a model for cognitive impairment. J Psychopharmacol. 2002;16(4):337-43.

252. van der Post J, Schram MT, Schoemaker RC, Pieters MS, Fuseau E, Pereira A, et al. CNS effects of sumatriptan and rizatriptan
in healthy female volunteers. Cephalalgia. 2002;22(4):271-81.

253. van der Post JP, de Visser SJ, de Kam ML, Woelfler M, Hilt DC, Vornov J, et al. The central nervous system effects,
pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. Br J Clin Pharmacol. 2005;60(2):128-36.

254. van der Post JP, de Visser SJ, Schoemaker RC, Cohen AF, van Gerven JM. Pharmacokinetic/pharmacodynamic assessment of
tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients. J Psychopharmacol.
2004;18(2):221-7.

255. van der Vorst MM, Kist-van Holthe JE, den Hartigh J, van der Heijden AJ, Cohen AF, Burggraaf J. Absence of tolerance and
toxicity to high-dose continuous intravenous furosemide in haemodynamically unstable infants after cardiac surgery. Br J Clin Pharmacol.
2007;64(6):796-803.

256. van der Vorst MM, Ruys-Dudok van Heel I, Kist-van Holthe JE, den Hartigh J, Schoemaker RC, Cohen AF, et al. Continuous
intravenous furosemide in haemodynamically unstable children after cardiac surgery. Intensive Care Med. 2001;27(4):711-5.

257. van Dongen MG, Geerts BF, Bhanot S, Morgan ES, de Kam ML, Moerland M, et al. Characterization of a standardized glucagon
challenge test as a pharmacodynamic tool in pharmacological research. Horm Metab Res. 2014;46(4):269-73.

258. van Dongen MG, Geerts BF, Morgan ES, Brandt TA, de Kam ML, Romijn JA, et al. First proof of pharmacology in humans of a
novel glucagon receptor antisense drug. J Clin Pharmacol. 2015;55(3):298-306.

259. van Doorn MB, Burggraaf J, van Dam T, Eerenberg A, Levi M, Hack CE, et al. A phase I study of recombinant human C1
inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol. 2005;116(4):876-83.

260. van Doorn MB, Espirito Santo SM, Meijer P, Kamerling IM, Schoemaker RC, Dirsch V, et al. Effect of garlic powder on C-
reactive protein and plasma lipids in overweight and smoking subjects. Am J Clin Nutr. 2006;84(6):1324-9.

261. van Everdingen JJ, Cohen AF. Self-experimentation by doctors. Lancet. 1990;336(8728):1448.

262. Van Gerven JM, Gijsman HJ, Verkes RJ, Cohen AF. [Cognitive and psychotic effects after cessation of chronic cannabis use].
Ned Tijdschr Geneeskd. 1998;142(18):1046-7.

263. van Gerven JM, Roncari G, Schoemaker RC, Massarella J, Keesmaat P, Kooyman H, et al. Integrated pharmacokinetics and
pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male
subjects. Br J Clin Pharmacol. 1997;44(5):487-93.

264. van Gerven JM, Schoemaker RC, Jacobs LD, Reints A, Ouwersloot-van der Meij MJ, Hoedemaker HG, et al. Self-medication of
a single headache episode with ketoprofen, ibuprofen or placebo, home-monitored with an electronic patient diary. Br J Clin Pharmacol.
1996;42(4):475-81.

265. van Gerven JM, Uchida E, Uchida N, Pieters MS, Meinders AJ, Schoemaker RC, et al. Pharmacodynamics and pharmacokinetics
of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers. J
Clin Pharmacol. 1998;38(12):1129-36.

266. van Griensven JM, Burggraaf KJ, Gerloff J, Gunzler WA, Beier H, Kroon R, et al. Effects of changing liver blood flow by
exercise and food on kinetics and dynamics of saruplase. Clin Pharmacol Ther. 1995;57(4):381-9.

267. van Griensven JM, Huisman LG, Stuurman T, Dooijewaard G, Kroon R, Schoemaker RC, et al. Effects of increased liver blood
flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator. Clin Pharmacol Ther. 1996;60(5):504-11.

268. van Griensven JM, Jusko WJ, Lemkes HH, Kroon R, Verhorst CJ, Chiang ST, et al. Tolrestat pharmacokinetic and
pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes. Clin
Pharmacol Ther. 1995;58(6):631-40.

269. van Griensven JM, Koster RW, Burggraaf J, Huisman LG, Kluft C, Kroon R, et al. Effects of liver blood flow on the
pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction. Clin
Pharmacol Ther. 1998;63(1):39-47.

270. van Griensven JM, Koster RW, Hopkins GR, Beier H, Gunzler WA, Kroon R, et al. Effect of changes in liver blood flow on the
pharmacokinetics of saruplase in patients with acute myocardial infarction. Thromb Haemost. 1997;78(3):1015-20.

271. van Griensven JM, Schoemaker RC, Cohen AF, Luus HG, Seibert-Grafe M, Rothig HJ. Pharmacokinetics, pharmacodynamics
and bioavailability of the ACE inhibitor ramipril. Eur J Clin Pharmacol. 1995;47(6):513-8.

272. van Griensven JM, Seibert-Grafe M, Schoemaker HC, Frolich M, Cohen AF. The pharmacokinetic and pharmacodynamic
interactions of ramipril with propranolol. Eur J Clin Pharmacol. 1993;45(3):255-60.

273. van Haarst AD, Dijkmans AC, Weimann HJ, Kemme MJ, Bosch JJ, Schoemaker RC, et al. Clinically important interaction
between tedisamil and verapamil. J Clin Pharmacol. 2009;49(5):560-7.

274. Van Haarst AD, Van Gerven JM, Cohen AF, De Smet M, Sterrett A, Birk KL, et al. The effects of moclobemide on the
pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers. Br J Clin Pharmacol. 1999;48(2):190-6.

275. van Haarst AD, van ‘t Klooster GA, van Gerven JM, Schoemaker RC, van Oene JC, Burggraaf J, et al. The influence of cisapride
and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther. 1998;64(5):542-6.

276. Van Hoogdalem EJ, Wackwitz AT, De Boer AG, Cohen AF, Breimer DD. Rate-controlled rectal absorption enhancement of
cefoxitin by co-administration of sodium salicylate or sodium octanoate in healthy volunteers. Br J Clin Pharmacol. 1989;27(1):75-81.

277. van Meer L, Moerland M, Cohen AF, Burggraaf J. Urinary kidney biomarkers for early detection of nephrotoxicity in clinical

drug development. Br J Clin Pharmacol. 2014;77(6):947-57.

278. van Meer L, Moerland M, Gallagher J, van Doorn MB, Prens EP, Cohen AF, et al. Injection site reactions after subcutaneous
oligonucleotide therapy. Br J Clin Pharmacol. 2016;82(2):340-51.

279. van Meir H, Nout RA, Welters MJ, Loof NM, de Kam ML, van Ham JJ, et al. Impact of (chemo)radiotherapy on immune cell
composition and function in cervical cancer patients. Oncoimmunology. 2017;6(2):e1267095.

280. van Poelgeest EP, Hodges MR, Moerland M, Tessier Y, Levin AA, Persson R, et al. Antisense-mediated reduction of proprotein
convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial. Br J Clin Pharmacol. 2015;80(6):1350-

281. Van Rooij J, Schoemaker HC, Bruno R, Reinhoudt JF, Breimer DD, Cohen AF. Cimetidine does not influence the metabolism of
the H1-receptor antagonist ebastine to its active metabolite carebastine. Br J Clin Pharmacol. 1993;35(6):661-3.

282. van Rooij J, van der Stegen GH, Schoemaker RC, Kroon C, Burggraaf J, Hollaar L, et al. A placebo-controlled parallel study of
the effect of two types of coffee oil on serum lipids and transaminases: identification of chemical substances involved in the cholesterol-
raising effect of coffee. Am J Clin Nutr. 1995;61(6):1277-83.

283. van Steveninck AL, Gieschke R, Schoemaker HC, Pieters MS, Kroon JM, Breimer DD, et al. Pharmacodynamic interactions of
diazepam and intravenous alcohol at pseudo steady state. Psychopharmacology (Berl). 1993;110(4):471-8.

284. van Steveninck AL, Gieschke R, Schoemaker RC, Roncari G, Tuk B, Pieters MS, et al. Pharmacokinetic and pharmacodynamic
interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol. 1996;41(6):565-73.

285. Van Steveninck AL, Mandema JW, Tuk B, Van Dijk JG, Schoemaker HC, Danhof M, et al. A comparison of the concentration-
effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity. Br J Clin Pharmacol. 1993;36(2):109-15.

286. van Steveninck AL, Pieters MS, Schoemaker HC, Breimer DD, Cohen AF. CNS-related performance and haemodynamics of
metoprolol-Oros and propranolol after single and 3 days dosing in healthy volunteers. Br J Clin Pharmacol. 1993;35(2):114-20.

287. van Steveninck AL, Schoemaker HC, den Hartigh J, Pieters MS, Breimer DD, Cohen AF. Effects of intravenous temazepam. II.
A study of the long-term reproducibility of pharmacokinetics, pharmacodynamics, and concentration-effect parameters. Clin Pharmacol
Ther. 1994;55(5):546-55.

288. van Steveninck AL, Schoemaker HC, den Hartigh J, Rijnkels J, Pieters MS, Breimer DD, et al. Effects of intravenous
temazepam. I. Saccadic eye movements and electroencephalogram after fast and slow infusion to pseudo steady state. Clin Pharmacol Ther.
1994;55(5):535-45.

289. van Steveninck AL, Schoemaker HC, Pieters MS, Kroon R, Breimer DD, Cohen AF. A comparison of the sensitivities of
adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers.
Clin Pharmacol Ther. 1991;50(2):172-80.

290. van Steveninck AL, van Berckel BN, Schoemaker RC, Breimer DD, van Gerven JM, Cohen AF. The sensitivity of
pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol.
1999;13(1):10-7.

291. van Steveninck AL, Verver S, Schoemaker HC, Pieters MS, Kroon R, Breimer DD, et al. Effects of temazepam on saccadic eye
movements: concentration-effect relationships in individual volunteers. Clin Pharmacol Ther. 1992;52(4):402-8.

292. van Steveninck AL, Wallnofer AE, Schoemaker RC, Pieters MS, Danhof M, van Gerven JM, et al. A study of the effects of long-
term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharmacol. 1997;44(3):267-75.

293. Verkes RJ, Gijsman HJ, Pieters MS, Schoemaker RC, de Visser S, Kuijpers M, et al. Cognitive performance and serotonergic
function in users of ecstasy. Psychopharmacology (Berl). 2001;153(2):196-202.

294. Visser WH, Burggraaf J, Muller LM, Schoemaker RC, Fowler PA, Cohen AF, et al. Pharmacokinetic and pharmacodynamic
profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther. 1996;60(4):452-60.

295. Wallnofer AE, Cohen AF. Good clinical practice: a question of balance. Br J Clin Pharmacol. 1993;35(5):449-50.

296. Wallnofer AE, van Griensven JM, Schoemaker HC, Cohen AF, Lambert W, Kluft C, et al. Effect of isotretinoin on endogenous
tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans. Thromb Haemost. 1993;70(6):1005-8.

297. Weijtens O, Feron EJ, Schoemaker RC, Cohen AF, Lentjes EG, Romijn FP, et al. High concentration of dexamethasone in
aqueous and vitreous after subconjunctival injection. Am J Ophthalmol. 1999;128(2):192-7.

298. Weijtens O, Schoemaker RC, Cohen AF, Romijn FP, Lentjes EG, van Rooij J, et al. Dexamethasone concentration in vitreous
and serum after oral administration. Am J Ophthalmol. 1998;125(5):673-9.

299. Weijtens O, Schoemaker RC, Lentjes EG, Romijn FP, Cohen AF, van Meurs JC. Dexamethasone concentration in the subretinal
fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. Ophthalmology. 2000;107(10):1932-8.

300. Weijtens O, Schoemaker RC, Romijn FP, Cohen AF, Lentjes EG, van Meurs JC. Intraocular penetration and systemic absorption
after topical application of dexamethasone disodium phosphate. Ophthalmology. 2002;109(10):1887-91.

301. Weijtens O, van der Sluijs FA, Schoemaker RC, Lentjes EG, Cohen AF, Romijn FP, et al. Peribulbar corticosteroid injection:
vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am J Ophthalmol. 1997;123(3):358-63.

302. Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, et al. Vaccination during myeloid cell
depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med. 2016;8(334):334ra52.

303. Westra AE, Bos W, Cohen AF. New EU clinical trials regulation. BMJ. 2014;348:g3710.

304. Westra AE, Sukhai RN, Wit JM, de Beaufort ID, Cohen AF. Acceptable risks and burdens for children in research without direct
benefit: a systematic analysis of the decisions made by the Dutch Central Committee. J Med Ethics. 2010;36(7):420-4.

305. Willner A, Kantrowitz AB, Cohen AF. Intrasphenoidal encephalocele: diagnosis and management. Otolaryngol Head Neck Surg.
1994;111(6):834-7.

306. Zoethout RW, de Kam ML, Dahan A, Cohen AF, van Gerven JM. A comparison of the central nervous system effects of alcohol
at pseudo-steady state in Caucasian and expatriate Japanese healthy male volunteers. Alcohol. 2012;46(7):657-64.

307. Zoethout RW, Iannone R, Bloem BR, Palcza J, Murphy G, Chodakewitz J, et al. The effects of a novel histamine-3 receptor
inverse agonist on essential tremor in comparison to stable levels of alcohol. J Psychopharmacol. 2012;26(2):292-302.

308. Zoethout RW, Schoemaker RC, Zuurman L, van Pelt H, Dahan A, Cohen AF, et al. Central nervous system effects of alcohol at a
pseudo-steady-state concentration using alcohol clamping in healthy volunteers. Br J Clin Pharmacol. 2009;68(4):524-34.

309. Zoethout RW, van Gerven JM, Dumont GJ, Paltansing S, van Burgel ND, van der Linden M, et al. A comparative study of two
methods for attaining constant alcohol levels. Br J Clin Pharmacol. 2008;66(5):674-81.

310. Zuiker RG, Kamerling IM, Morelli N, Calderon C, Boot JD, de Kam M, et al. Reproducibility of biomarkers in induced sputum
and in serum from chronic smokers. Pulm Pharmacol Ther. 2015;33:81-6.

311. Zuiker RG, Tribouley C, Diamant Z, Boot JD, Cohen AF, Van Dyck K, et al. Sputum RNA signature in allergic asthmatics
following allergen bronchoprovocation test. Eur Clin Respir J. 2016;3:31324.

312. Zuurman L, Passier PC, de Kam M, Kleijn HJ, Cohen AF, van Gerven JM. Pharmacodynamic and pharmacokinetic effects of the
intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers. J Psychopharmacol. 2009;23(6):633-44.

313. Zuurman L, Passier PC, de Kam ML, Kleijn HJ, Cohen AF, van Gerven JM. Pharmacodynamic and pharmacokinetic effects of
the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers. J Psychopharmacol. 2010;24(11):1689-96.

314. Zuurman L, Roy C, Schoemaker RC, Amatsaleh A, Guimaeres L, Pinquier JL, et al. Inhibition of THC-induced effects on the
central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625. J Psychopharmacol. 2010;24(3):363-71.

315. Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, Bender JC, et al. Effect of intrapulmonary
tetrahydrocannabinol administration in humans. J Psychopharmacol. 2008;22(7):707-16.

[/wm_item][/wm_tabs][/vc_column][/vc_row]